Connect with us


The Generalitat awards Werfen the delivery of reagents at Vall d’Hebron

The Generalitat awards Werfen the delivery of reagents at the Vall d’Hebron for up to $959,000 (€791,000). The Barcelona-based company is committed to offer this service at least until the end of 2022 for more than $479,600 (€395,400) per year. The supply of reagents and equipment does not allow, given its nature, the division of this contract into lots because would make the execution of the tender difficult and risky.



The Catalan Government resolves a new contract in cytogenetics. The regional executive has awarded Werfen the delivery of reagents to the Vall d’Hebron Hospital for up to $959,000 (€791,000), according to the community’s contracting profile. 

Werfen will supply this Barcelona hospital with reagents and equipment for fish techniques for the anatomical pathology, hematology, and genetics departments. The fish technique is a laboratory practice to detect and locate a specific DNA sequence in a chromosome. The technique is based on exposing chromosomes to a small DNA sequence called a probe that has a fluorescent molecule attached to it. This operator has been awarded the contract for a period of two years, although an extension of two more years, until 2024, is foreseen. 

The annual payments contemplate a payment of $198,200 (€163,420) plus  $41,530 (€34,318.2) VAT. Therefore, if only the two years of the contract are fulfilled, the amount would be  $479,740 (€395,476.4) (VAT included).  

Read more on the subject and find other important finance news with our companion app, Born2Invest.

The Generalitat has agreed with the company a payment of more than $198,000 (€163,400) per year 

The supply of reagents and equipment does not allow, given its nature, the division of this contract into lots because the distribution with different suppliers would make the execution of the tender difficult and risky. This tender includes the supply of LSI probe for oncology, dual color LSI probe, tricolor probe or chromosome painting probe, among others.

The winning bidder, Werfen, is a Catalan medical technology company that operates directly in almost thirty countries and in more than one hundred territories through distributors. The company has its headquarters in Plaza Europa, in L’Hospitalet de Llobregat (Barcelona), a delegation in Alcobendas (Madrid) and a logistics center in Tarancón (Cuenca). The company is controlled by the Rubiralta family. Since January 2019, the presidency of the group has been held by Marc Rubiralta Giralt, after his brother, Jordi Rubiralta, stepped down after seven years at the helm. 

Jordi Rubiralta Giralt, the eldest of the four members of the second generation, took the reins of the group in January 2012, months before the death of his father, José María Rubiralta Vilaseca, founder of Werfen.  

Werfen operates in more than 100 countries around the world through distributors 

The company achieved a turnover of $1.78 million (€1.47 million) in 2019, up 6.1% from the previous year. By geography, Western Europe and North America continue to be the main markets for Werfen, with 40% and 27% of the business, respectively. AsiaPacific is the region with the highest expectations for future growth. This was the case in 2019, with growth of 12.9% going on to represent 18% of the Spanish group’s total business. Consolidated net profit stood at $99.4 million (€82 million), up 13%, while gross operating profit (EBITDA) exceeded $418,000 (€345 million), up 11% compared to 2018.


(Featured image by AdinaVoicu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.